A detailed history of Kbc Group Nv transactions in Arvinas, Inc. stock. As of the latest transaction made, Kbc Group Nv holds 1,630 shares of ARVN stock, worth $30,122. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,630
Previous 1,630 -0.0%
Holding current value
$30,122
Previous $43,000 6.98%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 08, 2024

BUY
$36.38 - $52.31 $59,299 - $85,265
1,630 New
1,630 $67,000
Q3 2023

Feb 15, 2024

BUY
$19.64 - $28.21 $14,887 - $21,383
758 New
758 $15,000

Others Institutions Holding ARVN

About ARVINAS, INC.


  • Ticker ARVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,205,300
  • Market Cap $983M
  • Description
  • Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...
More about ARVN
Track This Portfolio

Track Kbc Group Nv Portfolio

Follow Kbc Group Nv and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kbc Group Nv, based on Form 13F filings with the SEC.

News

Stay updated on Kbc Group Nv with notifications on news.